Clinical and biochemical studies with controlled-release levodopa/carbidopa

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

In five patients with parkinsonism, the optimal dosage of a controlled-release levodopa/carbidopa preparation (CR-3) was three times higher than the dosage of Sinemet and produced higher plasma levodopa concentrations, but did not reduce the fluctuations in plasma levodopa or clinical response. Plasma levodopa concentrations were higher and clinical responses better before the first dose of the day with CR-3. CR-3 treatment benefited two patients, reducing the severity of off periods and off dystonia. Two patients were worse on CR-3 despite higher plasma levodopa levels than those adequate for clinical response to Sinemet or levodopa infusions. CR-3 could benefit a few severely affected patients, but it is necessary to understand the factors that affect absorption of levodopa from sustained-release preparations, as well as the consequences of prolonged elevation of plasma levodopa levels.

Original languageEnglish (US)
Pages (from-to)1206-1211
Number of pages6
JournalNeurology
Volume36
Issue number9
StatePublished - 1986

Fingerprint

Levodopa
Delayed-Action Preparations
Dystonia
Parkinsonian Disorders
Clinical Studies
levodopa drug combination carbidopa
Controlled
Plasma

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology
  • Neuroscience(all)

Cite this

Clinical and biochemical studies with controlled-release levodopa/carbidopa. / Nutt, John; Woodward, William; Carter, Julie.

In: Neurology, Vol. 36, No. 9, 1986, p. 1206-1211.

Research output: Contribution to journalArticle

@article{4d414dfedb884625b69b909890c74d3b,
title = "Clinical and biochemical studies with controlled-release levodopa/carbidopa",
abstract = "In five patients with parkinsonism, the optimal dosage of a controlled-release levodopa/carbidopa preparation (CR-3) was three times higher than the dosage of Sinemet and produced higher plasma levodopa concentrations, but did not reduce the fluctuations in plasma levodopa or clinical response. Plasma levodopa concentrations were higher and clinical responses better before the first dose of the day with CR-3. CR-3 treatment benefited two patients, reducing the severity of off periods and off dystonia. Two patients were worse on CR-3 despite higher plasma levodopa levels than those adequate for clinical response to Sinemet or levodopa infusions. CR-3 could benefit a few severely affected patients, but it is necessary to understand the factors that affect absorption of levodopa from sustained-release preparations, as well as the consequences of prolonged elevation of plasma levodopa levels.",
author = "John Nutt and William Woodward and Julie Carter",
year = "1986",
language = "English (US)",
volume = "36",
pages = "1206--1211",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Clinical and biochemical studies with controlled-release levodopa/carbidopa

AU - Nutt, John

AU - Woodward, William

AU - Carter, Julie

PY - 1986

Y1 - 1986

N2 - In five patients with parkinsonism, the optimal dosage of a controlled-release levodopa/carbidopa preparation (CR-3) was three times higher than the dosage of Sinemet and produced higher plasma levodopa concentrations, but did not reduce the fluctuations in plasma levodopa or clinical response. Plasma levodopa concentrations were higher and clinical responses better before the first dose of the day with CR-3. CR-3 treatment benefited two patients, reducing the severity of off periods and off dystonia. Two patients were worse on CR-3 despite higher plasma levodopa levels than those adequate for clinical response to Sinemet or levodopa infusions. CR-3 could benefit a few severely affected patients, but it is necessary to understand the factors that affect absorption of levodopa from sustained-release preparations, as well as the consequences of prolonged elevation of plasma levodopa levels.

AB - In five patients with parkinsonism, the optimal dosage of a controlled-release levodopa/carbidopa preparation (CR-3) was three times higher than the dosage of Sinemet and produced higher plasma levodopa concentrations, but did not reduce the fluctuations in plasma levodopa or clinical response. Plasma levodopa concentrations were higher and clinical responses better before the first dose of the day with CR-3. CR-3 treatment benefited two patients, reducing the severity of off periods and off dystonia. Two patients were worse on CR-3 despite higher plasma levodopa levels than those adequate for clinical response to Sinemet or levodopa infusions. CR-3 could benefit a few severely affected patients, but it is necessary to understand the factors that affect absorption of levodopa from sustained-release preparations, as well as the consequences of prolonged elevation of plasma levodopa levels.

UR - http://www.scopus.com/inward/record.url?scp=0022512759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022512759&partnerID=8YFLogxK

M3 - Article

C2 - 3748387

AN - SCOPUS:0022512759

VL - 36

SP - 1206

EP - 1211

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 9

ER -